Ask the expert: How to spot fake Parkinson’s medicines online
Author: Caithlin NgPublished: 27 February 2020
Prep: Cook: Serves:
In the third in our expert series, we talk to Mike Isles, Executive Director of the Alliance for Safe Online Pharmacy in the EU, about the growing problem of fake Parkinson’s medicines advertised and sold online – from their shocking prevalence to top tips on how to stay safe
Firstly, could you explain to our readers what falsified medicines are?
Falsified, fake or counterfeit medicines are medicines disguising themselves as authentic. They can pose significant health risks and might contain ingredients that are of bad or toxic quality, or they might provide the wrong dosage of active ingredients or an altogether different product. They haven’t been checked for quality, safety and efficacy against the EU’s strict regulations for healthcare products, making them a real risk to your health.
You work for the Alliance for Safe Online Pharmacy. What is it and what are its key aims?
The Alliance for Safe Online Pharmacy (ASOP EU) was created in 2011 to raise public awareness about the growing problem of falsified medicines online for European patients. ASOP EU works to encourage development and maintenance of a safe and secure environment in which patients and caregivers may access medications online, if they so choose. This is a complex problem that requires a multifactorial approach – criminals are offering falsified medicines to European citizens on not just 35,000 illegally operating websites, but also through social media and e-commerce platforms.
How common are falsified Parkinson’s medications?
It is difficult to pinpoint the number of websites offering Parkinson’s medications online, but law enforcement officials around the world take down websites and seize packages – many thousands – with falsified medicines every year, including neurological medicines and other highly-coveted prescription drugs. It is clear that if there is a market for a medication, criminals will want to produce falsified versions to meet it. These illegal actors will place any potential profits above public health and patient safety, especially in areas where there is consumer demand.
What are some actions that policymakers can take?
The Falsified Medicines Directive has been an excellent lever for helping to secure the legitimate supply chain – this comprises the manufacturer, wholesaler, pharmacist and patient. However, the illegal online pharmacy websites operate outside of the highly-regulated bricks-and-mortar supply chain, so governments should look at the various points of entry that use the internet to ensure they are operating safely for the public.
How aware are people of these scams?
Ninety-six per cent of websites selling medicine are operating illegally, but a survey from ASOP EU’s website found that on average just over 50% of people are unaware of this. Having recognised the pervasive threat of illegal online drug sellers a very high proportion, in fact greater than 90%, indicated a potential change in their behaviour, such as seeking out a bricks-and-mortar pharmacy or an authentic internet pharmacy. Our educational approach appears to be working.
What are your top tips for Parkinson’s community to safely buy medicine online?
The best tip to avoid buying medicine
from an illegal online pharmacy is to verify three main items: a licensed
pharmacist present on site, a physical address for operations, and a working
telephone number. Patients should be wary of websites that offer bulk discounts,
too-good-to-be-true prices, or outrageous results, and very importantly that do
not require a valid prescription.
Under the EU’s Falsified Medicines Directive, any retailer in a member state must also register with their local health authority to sell medicine online; they are then legally obliged to put a “common logo” on their website. In the UK, patients can check whether the seller is registered on the Medicines and Healthcare products Regulatory Agency website.
Who can the public consult if they are still unsure?
The first port of call should be their
pharmacist or other healthcare provider, who will be knowledgeable about the
situation. Because falsified medicines sold online are designed to look as much
as possible like the original product, it can be virtually impossible to tell
the difference. It is also important not to be duped into thinking that
medicines with no legitimate product licence for use in EU member states –
therefore accompanied by insufficient clinical evidence – will work and have
In addition ASOP EU and its sister non-profit organisation ASOP Global has a wealth of information about this important area, which can be found at buysaferx.pharmacy.
There are lots of people in this world who are not aware of the rigorous clinical tests to prove safety and effectiveness before a medicine receives its licence – and so people can be very vulnerable and willing to try anything because conventional medicine isn’t working or has become unaffordable.
Need to know: Mike Isles is Executive Director of the Alliance for Safe Online
Pharmacy in the EU, an organisation addressing the threat of illegal online
drug sales. He has had a long career in the pharmaceuticals industry and has
since spent the last 10 years devoting his time to patient safety issues.
At a glance: fake medicines online
Fake medicines, which can pose significant health risks, are sold on around 35,000 websites and via social media and e-commerce platforms.
96% of websites selling medicines operate illegally – but a survey suggests that over 50% of people are not aware of this.
It can be difficult to see the difference between fake and authentic medicines, as they are designed to look similar.
Internet users should confirm that an online pharmacy lists a licensed pharmacist, a physical operational address, a working telephone number and requires a valid prescription before placing an order.
“It’s a positive and uplifting event during uncertain times”
How a virtual concert is supporting Parkinson’s disease speech therapy
3 months ago
35 new Parkinson’s drug trials launched in last year
Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.